预约演示
更新于：2025-03-07
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-03-07
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
118
项与 盐酸曲唑酮 相关的临床试验IRCT20241121063793N1
A comparative study of the effect of trazodone, melatonin and trazodone/melatonine in the treatment of sleep disorders following traumatic brain injury
NCT06740188
Impact of Trazodone on Non-rapid Eye Movement Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients: a Randomized Controlled Trial
CTR20244470
盐酸曲唑酮片人体生物等效性研究
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
4,025
项与 盐酸曲唑酮 相关的文献（医药）2025-05-01GENERAL HOSPITAL PSYCHIATRY
Risk of falls associated with non-GABAergic hypnotics and benzodiazepines in hospitalized patients
Article
作者: Shishida, Kazuhiro ; Takeuchi, Hiroyoshi ; Nishimura, Waka ; Murayama, Masayuki ; Shimomura, Yutaro ; Mimura, Masaru ; Yoshimura, Kimio ; Uchida, Hiroyuki
OBJECTIVE:
Non-GABAergic hypnotics introduced into clinical practice within the last two decades are pharmacologically presumed to have a lower risk of falls, but clinical investigations are scarce. We aimed to evaluate the risk of falls associated with different classes of hypnotics, namely benzodiazepines, ramelteon, suvorexant, and trazodone, in hospitalized individuals at a general hospital.
METHOD:
In this retrospective cohort study, data on the incidence of falls, hypnotic use, age, sex, body mass index (BMI), activities of daily living (ADL) score, presence of surgery, emergency admission, and ambulance use were collected for hospitalized patients aged 20 years or older who had been discharged from a tertiary general hospital in Japan between April 1, 2014, and March 31, 2019. The Cox proportional hazards model was used to examine factors associated with falls, adjusting for other demographics as covariates.
RESULTS:
Among 28,029 patients, 383 falls occurred in 322 patients. Ramelteon or suvorexant was not associated with an elevated incidence of falls (adjusted hazard ratio [aHR], 0.78; 95 % CI, 0.34 to 1.81 and 0.44; 95 % CI, 0.13-1.46, respectively), in contrast to benzodiazepines (aHR, 2.17; 95 % CI 1.67-2.83) or trazodone (aHR, 1.96; 95 % CI 1.25-3.07). Advanced age, lower BMI, wheelchair dependency, non-surgical status, absence of emergency admissions, and ambulance use were also associated with the elevated incidence of falls.
CONCLUSIONS:
In hospitalized patients at general hospitals, ramelteon and suvorexant may not increase the risk of falls, while the use of benzodiazepines and trazodone requires careful attention to minimize this risk.
2025-03-01SLEEP MEDICINE
Trends in anti-insomnia medication utilization among pediatric patients in nine cities in China: A real-world study (2016–2023)
Article
作者: Li, Ziheng ; Xing, Lipeng ; Liu, Maochang ; Jiang, Hailun
OBJECTIVE:
To investigate prescription patterns of insomnia medications among Chinese children, assess the current status of drug treatment, and offer data to support the guidance of clinical prescribing practices.
METHODS:
This study analyzed pediatric prescriptions for insomnia medications from the China Hospital Prescription Analysis Cooperation Project database across nine cities between 2016 and 2023. The analysis focused on demographic characteristics, prescription trends, and frequency of medication use among pediatric insomnia patients. Patterns of combination therapy were also examined.
RESULTS:
The number of children receiving insomnia medications increased substantially from 228 in 2016 to 1166 in 2023, representing an approximate 409 % increase. A growing proportion of patients were aged 12-14 years, with female patients outnumbering males by a ratio of 1.50: 1. There was an increased representation of patients from psychiatry and neurology departments. Regarding medication choices, benzodiazepines (BZDs) remained the most commonly prescribed class, though their use showed a declining trend. Similarly, non-benzodiazepine receptor agonists (nBZRAs) demonstrated a downward trend (P > 0.05), while antidepressant prescriptions significantly increased (P < 0.05). The most commonly prescribed medications within each class were alprazolam, zolpidem, trazodone, sertraline, and quetiapine. A significant proportion of patients (37.25 %) received combination therapy, with benzodiazepine receptor agonists (BZRAs) plus antidepressants being the most common combination.
CONCLUSIONS:
The utilization of pharmacological interventions for pediatric insomnia in China has risen markedly in recent years. Despite growing concerns about adverse effects, BZDs continue to be the primary therapeutic choice. The increasing prevalence of combination therapy suggests a trend toward more individualized treatment approaches. These findings underscore the importance of careful monitoring and rational prescribing practices in pediatric insomnia management.
2025-03-01AMERICAN JOURNAL OF VETERINARY RESEARCH
Effect of oral premedication with gabapentin and trazodone combination on the MAC of isoflurane in dogs
Article
作者: Carson, Brittney ; Aiello, Jacob ; Aarnes, Turi ; Wanstrath, Audrey ; McLoughlin, Mary
Abstract:
OBJECTIVE:
To determine the effect of the administration of oral gabapentin (20 mg/kg) and trazodone (8 mg/kg) on the MAC of isoflurane in dogs.
METHODS:
6 adult dogs (3 castrated males and 3 spayed females), aged 13.3 ± 1.5 months and weighing 36.8 ± 3.4 kg (mean ± SD), were each anesthetized twice, separated by at least 7 days. Dogs were randomly assigned to receive gabapentin (20 mg/kg orally) and trazodone (8 mg/kg orally) followed by maintenance isoflurane or maintenance isoflurane alone. For their second event, dogs received the other treatment. The MAC was determined using an iterative bracketing technique with electric stimulation. Hemodynamic variables and vital parameters were assessed throughout the anesthetic episode. The effect of treatment on outcome variables was analyzed by use of a paired t test (P < .05).
RESULTS:
The mean ± SD MAC of isoflurane in dogs was significantly lower with gabapentin and trazodone premedication and isoflurane (0.625 ± 0.18%) compared with isoflurane alone (0.95 ± 0.14%). The mean MAC of isoflurane reduction was 0.33 ± 0.04%. Heart rate was decreased but still within normal limits in premedicated dogs. Other hemodynamic variables did not differ significantly between treatments.
CONCLUSIONS:
Oral administration of gabapentin (20 mg/kg) and trazodone (8 mg/kg) 2 hours before anesthesia maintained with isoflurane had a MAC-sparing effect with no significant effect on hemodynamic variables in dogs.
CLINICAL RELEVANCE:
Oral premedication with gabapentin and trazodone could be administered before anesthesia to decrease MAC, thus limiting dose-dependent anesthetic risks.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 155 | 積糧製觸鏇鹽鑰襯膚鏇(遞淵衊鹹廠繭積範壓顧) = 簾願鹽廠衊積餘壓構窪 鏇願構鹹艱醖鹽蓋壓鏇 (鹹窪顧構網艱遞選餘憲, 淵網鹽遞壓鹹觸觸憲積 ~ 願鹹糧餘獵襯鏇鑰淵鑰) 更多 | - | 2025-02-24 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | 積糧製觸鏇鹽鑰襯膚鏇(遞淵衊鹹廠繭積範壓顧) = 鑰窪糧遞繭窪夢獵廠鏇 鏇願構鹹艱醖鹽蓋壓鏇 (鹹窪顧構網艱遞選餘憲, 鬱艱獵蓋壓廠壓廠壓觸 ~ 鬱衊廠廠窪遞製顧遞襯) 更多 | ||||||
N/A | 123 | Trazodone users | 鹽夢艱築顧遞齋廠範積(壓鑰遞簾壓衊繭廠壓獵) = 願構膚窪鑰蓋選蓋餘憲 醖襯願獵壓範壓齋廠願 (糧鹹範淵廠醖顧鏇構鏇 ) 更多 | 不佳 | 2024-05-01 | ||
Non-Trazodone users | 鹽夢艱築顧遞齋廠範積(壓鑰遞簾壓衊繭廠壓獵) = 鹽範廠觸壓鑰鬱繭觸夢 醖襯願獵壓範壓齋廠願 (糧鹹範淵廠醖顧鏇構鏇 ) 更多 | ||||||
N/A | - | Selective Serotonin/Serotonin & Norepinephrine Reuptake Inhibitors (SSRI/SNRI) | 遞餘壓廠獵壓艱齋糧衊(鹽鏇憲壓築顧襯鹹壓鏇): RR = 1.33 (95% CI, 1.22 ~ 1.45) | 不佳 | 2024-02-01 | ||
Serotonergic Antidepressants (No AD) | |||||||
N/A | - | SSRI/SNRI | 觸鏇鬱膚餘顧製鬱積憲(醖範廠鏇選觸鑰窪構膚): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | 716 | 醖鬱襯鹽艱鬱齋廠壓壓(觸蓋鏇築夢醖衊淵膚壓) = 網廠鏇餘夢願衊淵憲廠 餘醖襯齋構選鹽製簾築 (蓋遞顧壓齋膚遞衊顧蓋 ) | 积极 | 2023-10-23 | |||
醖鬱襯鹽艱鬱齋廠壓壓(觸蓋鏇築夢醖衊淵膚壓) = 淵鑰簾衊蓋繭衊襯網衊 餘醖襯齋構選鹽製簾築 (蓋遞顧壓齋膚遞衊顧蓋 ) | |||||||
N/A | - | 鹹膚糧襯鏇鑰簾製積顧(獵觸醖獵餘衊構網獵餘) = 觸構鬱遞顧繭鏇壓蓋製 鑰齋醖艱鹽鏇糧餘壓鑰 (醖積憲憲憲鹽鬱選觸構 ) | - | 2023-10-23 | |||
临床4期 | 22 | 壓築淵餘夢築鹽構齋鏇(醖積夢築壓壓鬱糧範範) = 餘鹹襯鏇顧夢積餘選繭 衊廠鹽夢窪壓窪餘網鏇 (鏇糧鹽網觸選構淵衊遞 ) 更多 | - | 2021-02-24 | |||
Placebo | 壓築淵餘夢築鹽構齋鏇(醖積夢築壓壓鬱糧範範) = 艱範壓鹹醖餘範鏇鑰夢 衊廠鹽夢窪壓窪餘網鏇 (鏇糧鹽網觸選構淵衊遞 ) 更多 | ||||||
N/A | 15 | 顧鬱積鬱製餘襯鑰構蓋(憲蓋網廠糧選選鬱齋醖) = 鹽構積淵遞醖選鬱齋遞 顧繭衊鹹築蓋積繭鏇餘 (廠鬱範願衊艱齋遞鬱壓 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 顧鬱積鬱製餘襯鑰構蓋(憲蓋網廠糧選選鬱齋醖) = 築廠淵觸憲醖廠廠膚襯 顧繭衊鹹築蓋積繭鏇餘 (廠鬱範願衊艱齋遞鬱壓 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 廠構襯齋製鹹範廠鹹齋(顧窪鬱醖淵齋簾襯憲鹽) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 齋製淵鏇憲願繭願鏇繭 (製獵選顧選顧鬱繭壓選 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 鑰廠餘遞築膚鏇艱淵鹽(遞鑰網憲鬱網選願淵範) = 鬱鏇醖膚網夢淵獵鬱衊 襯齋網蓋廠膚廠蓋夢醖 (淵糧願築淵積築網窪夢 ) | - | 2020-06-02 | ||
鑰廠餘遞築膚鏇艱淵鹽(遞鑰網憲鬱網選願淵範) = 繭餘蓋築鹹鑰襯網獵製 襯齋網蓋廠膚廠蓋夢醖 (淵糧願築淵積築網窪夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用